Five series. One for each goal.

The Metabolic Series covers the most studied and commercially successful molecules of the past decade in weight control and type 2 diabetes: GLP-1 receptor agonists. They work by mimicking a gut hormone the body releases after meals, slowing gastric emptying, suppressing appetite at the hypothalamic level, and improving pancreatic insulin sensitivity.

Each generation adds a mechanism: Semaglutide is a mono-agonist (GLP-1 only), FDA-approved for obesity in 2021 with average 14.9% body weight reduction over 68 weeks. Tirzepatide is dual (GLP-1 + GIP), approved 2023, 22.5% reduction. Retatrutide is triple (GLP-1 + GIP + glucagon), still in Phase III, but its Phase II reported 24.2% reduction over 48 weeks — the highest figure on record in its category.

Typical use: research in obesity, insulin resistance, metabolic syndrome, NAFLD. Subcutaneous application 1×/week. Choice between the three depends on the goal: Semaglutide to enter gradually, Tirzepatide for consolidated results, Retatrutide for frontier research with the highest upside.

The Recovery Series brings together the two most-used molecules in tissue regeneration and high-performance sports: BPC-157 (Body Protection Compound) and TB-500 (Thymosin β-4 fragment). They work via complementary mechanisms — BPC-157 accelerates local angiogenesis and healing of tendons, ligaments, gastric mucosa, and neural tissue; TB-500 modulates cellular actin, facilitating stem-cell migration to injury sites.

BPC-157 is a pentadecapeptide isolated from human gastric juice. Over 100 animal-model papers document effects on musculoskeletal injuries, ulcers, and neural repair. TB-500 is the synthetic version of the active residue of Thymosin β-4, a protein present in virtually every cell in the body.

Typical use: research in chronic sports injuries, post-surgical recovery, tendon damage, inflammatory bowel conditions. Often stacked in 4–8 week protocols: BPC-157 daily, TB-500 twice weekly. It's been the reference combination in biohacker literature since 2015.

The Longevity Series is one of the oldest in the peptide category and, paradoxically, the one experiencing the strongest scientific renaissance. GHK-Cu (Glycyl-Histidyl-Lysine + copper ion) was identified in 1973 by researcher Pickart in human plasma, where its concentration drops approximately 60% between ages 20 and 60. This decline correlates with many aging markers.

GHK-Cu's mechanism is multifaceted: it modulates expression of more than 4,000 genes (per Pickart 2018 transcriptomic analysis), including DNA repair genes, endogenous antioxidants, and type III collagen production. It has applications in both topical use (premium cosmetics, where it dominates anti-aging formulations from brands like SkinMedica) and systemic research (subcutaneous or sublingual).

Typical use: research in skin regeneration, hair quality, cellular antioxidation, inflammatory modulation. GHK-Cu's appearance is naturally blue from copper chelation — the only molecule in the catalog with visible color. Applied daily in 30–60 day cycles.

The Hormonal Series addresses one of the most studied endocrine axes in aging: the somatotropic axis, responsible for growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. Both decline progressively from age 30.

This series uses secretagogues — peptides that stimulate the pituitary itself to release endogenous GH, instead of injecting exogenous GH. The canonical combination is CJC-1295 + Ipamorelin, which works via two synergistic pathways: CJC-1295 mimics GHRH (GH-releasing factor) increasing pulse amplitude; Ipamorelin activates the ghrelin receptor increasing frequency. The result is a pulsatile release profile that respects natural circadian rhythm — more physiological than injected GH.

Typical use: research in body composition, deep sleep quality (REM phase), muscle recovery, endocrine optimization for those over 35. Usually applied at night before sleep (when the body releases its natural GH peak). Ipamorelin is notably selective: unlike other secretagogues, it doesn't raise cortisol or prolactin, making it well-tolerated long-term.

The Premium Series brings together the most sophisticated molecules in the catalog — peptides with extensive clinical backing, clear regulatory profile, and more specific applications than the rest. This segment pays for quality above price.

Thymosin α-1 is the flagship case: it's an isolated fraction of natural thymosin, synthesized in the thymus gland. Its function is immune system modulation, particularly on T lymphocytes. It's approved for human clinical use in more than 35 countries (not yet in the USA) under the name Zadaxin, used as an adjuvant in hepatitis B/C, severe sepsis, and as immune support for oncology patients on chemotherapy.

Typical use: research in immune modulation, recovery from prolonged viral infection, support in autoimmune conditions, immune longevity for those over 50 (the thymus involutes with age). Applied 3 times weekly in 4–8 week cycles, with rest periods between cycles. Probably the peptide with the best evidence/safety-profile ratio in the entire catalog.